|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-0.91/--
|
Enterprise Value
27.14M
|
Balance Sheet |
Book Value Per Share
0.42
|
Cash Flow |
Cash Flow Yield
--
|
Income Statement |
Total Revenue
2.53M
|
Operating Revenue Per Share
0.00
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2024/05/20 14:47 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer. |